Utama › Adenokarsinoma Esofagus › Tennessee
Kajian klinikal Adenokarsinoma Esofagus di Tennessee
13 kajian untuk Adenokarsinoma Esofagus sedang mencari peserta di lokasi di Tennessee.
Bandar di Tennessee
Teks kajian rasmi (Bahasa Inggeris)
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Tennessee Oncology, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT07544589Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- University of Tennessee - Knoxville, Knoxville
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT06203600A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07090499A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07221149Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Baptist Cancer Center - Memphis, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06324357A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277413Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Nashville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT07182149A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06330064A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT06657144A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- US Oncology Research LLC, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Jul 2026 · NCT04389632Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- Gastrointestinal Associates, PC, Knoxville
Mengambil peserta
Umur 18 hingga 89 · Semua jantina · Dikemas kini 1 Jul 2026 · NCT05530343A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Mei 2026 · NCT05954312Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.